Scientists at the Joslin Diabetes Center are further investigating their own groundbreaking research into inflammation amongst type 2 diabetics . Their new clinical trial will investigate whether a common anti-inflammatory drug can influence blood glucose levels amongst those with type 2 diabetes.
If the trial proves to be successful, the role of salsalate (a drug often used to manage arthritic pain) could be crucial in treating diabetes in a cost effective way. The Joslin center is looking for approximately 800 adults who have a poor control over blood glucose levels to take part in a three-year study.
The clinical trials will be called the ‘Targeting Inflammation with Salsalate in Type 2 Diabetes (TINSAL T2D.) The principal investigator, Steven Shoelso, said: “This is the first large-scale study in patients that tests whether reducing inflammation can actually be used to treat diabetes. Given what we are learning about how type 2 diabetes develops, we think this might be getting at an underlying cause. We hope the study shows that targeting inflammation is a safe and inexpensive way to treat type 2 diabetes. We also hope that reducing inflammation decreases risk for coronary heart disease, which is another theory that we will be testing in a separate clinical study in the coming months.”
The news may be welcomed by healthcare services facing money problems and a tough future .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…